©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2318-2334
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2318
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2318
Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer
Ya-Kun Jiang, Meng Yue, Department of Gastroenterology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong Province, China
Wei Li, Health Management Center, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong Province, China
Ying-Yang Qiu, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore
Author contributions: Jiang YK wrote the manuscript; Li W and Qiu YY collected the data; Yue M guided the manuscript; all authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.
Conflict-of-interest statement: All the authors declare no conflict of interest.
Corresponding author: Meng Yue, MM, Doctor, Department of Gastroenterology, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Jinan 250013, Shandong Province, China. mengtiger78@163.com
Received: December 11, 2023
Revised: April 4, 2024
Accepted: April 18, 2024
Published online: June 15, 2024
Processing time: 186 Days and 19.7 Hours
Revised: April 4, 2024
Accepted: April 18, 2024
Published online: June 15, 2024
Processing time: 186 Days and 19.7 Hours
Core Tip
Core Tip: Human epidermal growth factor receptor 2 (HER2) is one of the most important targets in targeted therapy for gastric cancer. Trastuzumab combined with chemotherapy has been used as the first-line treatment for advanced gastric cancer. The safety and efficacy of pertuzumab and magtuximab in the treatment of gastric cancer have been verified. However, monoclonal antibodies, due to their large molecular weight, inability to penetrate the blood-brain barrier, and drug resistance, lead to decreased therapeutic efficacy, so it is necessary to explore the efficacy of other HER2-targeting therapies in gastric cancer.